Oxford Immunotec Global PLC (NASDAQ:OXFD) had its price objective reduced by investment analysts at Piper Jaffray Companies from $26.00 to $19.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has an “overweight” rating on the stock. Piper Jaffray Companies’ price target points to a potential upside of 21.17% from the company’s previous close.

Several other equities analysts have also recently weighed in on OXFD. Zacks Investment Research cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Cowen and Company restated a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. Finally, BTIG Research assumed coverage on Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $19.67.

Shares of Oxford Immunotec Global PLC (OXFD) traded down 8.514% during mid-day trading on Tuesday, hitting $14.345. 100,984 shares of the stock were exchanged. The stock’s 50 day moving average price is $16.23 and its 200-day moving average price is $15.75. The stock’s market capitalization is $331.03 million. Oxford Immunotec Global PLC has a 12-month low of $11.88 and a 12-month high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The business had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $25.05 million. During the same period last year, the business earned ($0.29) EPS. The business’s revenue was up 35.9% on a year-over-year basis. On average, equities research analysts expect that Oxford Immunotec Global PLC will post ($1.61) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global PLC (OXFD) PT Lowered to $19.00 at Piper Jaffray Companies” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/31/oxford-immunotec-global-plc-oxfd-pt-lowered-to-19-00-at-piper-jaffray-companies.html.

In other news, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the sale, the director now owns 18,000 shares in the company, valued at $284,760. The disclosure for this sale can be found here. Insiders have sold a total of 90,110 shares of company stock worth $1,523,514 over the last quarter. Company insiders own 8.11% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OXFD. New Leaf Venture Partners L.L.C. bought a new stake in shares of Oxford Immunotec Global PLC during the 4th quarter worth $20,594,000. Endurant Capital Management LP increased its holdings in Oxford Immunotec Global PLC by 3,456.1% in the 1st quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock worth $8,844,000 after acquiring an additional 554,915 shares during the last quarter. Redmile Group LLC increased its holdings in Oxford Immunotec Global PLC by 63.0% in the 2nd quarter. Redmile Group LLC now owns 1,428,094 shares of the company’s stock worth $12,853,000 after acquiring an additional 552,006 shares during the last quarter. AXA increased its holdings in Oxford Immunotec Global PLC by 52.5% in the 1st quarter. AXA now owns 917,468 shares of the company’s stock worth $14,212,000 after acquiring an additional 315,718 shares during the last quarter. Finally, RTW Investments LP increased its holdings in Oxford Immunotec Global PLC by 130.3% in the 4th quarter. RTW Investments LP now owns 543,287 shares of the company’s stock worth $8,122,000 after acquiring an additional 307,387 shares during the last quarter. Institutional investors own 79.21% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

The Fly

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.